Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02227251 · ClinicalTrials.gov registry record · Phase 2

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Karyopharm Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
244
Enrollment target
20
Study locations

NCT02227251: Recruiting Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Karyopharm Therapeutics.

NCT02227251 is a Phase 2 study of Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Karyopharm Therapeutics. The registered enrollment target is 244 participants, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02227251, a Phase 2 study of Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Karyopharm Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
244 participants
Enrollment target
20
Study locations

Study Summary

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

Primary Outcome

Assessed according to the revised response criteria based on the Guidelines of the International Working Group (IWG).

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG Selinexor

Study Locations (20)

Massachusetts

  • Dana Farber Cancer Institute - Boston
  • Tufts Medical Center - Boston
  • Lahey Clinic - Burlington
  • University of Massachusetts Medical School - Worcester

New York

  • Clinical Research Alliance - Lake Success
  • New York Presbyterian Hospital/ Cornell Medical College - New York
  • Stony Brook University Hospital - Stony Brook

Ohio

  • Gabrail Cancer Center - Canton
  • Cleveland Clinic Foundation - Cleveland
  • University Hospitals Seidman Cancer Center - Cleveland

California

  • University of California San Francisco - San Francisco
  • University of California Los Angeles (UCLA) - Santa Monica

Illinois

  • University of Chicago - Chicago
  • Robert H. Lurie Comprehensive Cancer Center/Northwestern University - Chicago

Arizona

  • UACC Arizona - Tucson

Florida

  • Boca Raton Cancer Research Medical Center - Plantation

Kentucky

  • Norton Cancer Institute - Louisville

Trial Details

FieldValue
Enrollment Target 244 participants
Start Date 2014-11
Est. Completion 2027-11
Phase Phase 2
Karyopharm Therapeutics

25 total trials

What NCT02227251 shows while recruiting

NCT02227251 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (12% higher).

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Selinexor is the first listed.

NCT02227251 names 20 study sites across 11 states, led by Massachusetts, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT02227251 about?

NCT02227251 is a clinical study titled "Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

What is the current status of trial NCT02227251?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2014-11. Estimated completion is 2027-11.

What conditions does trial NCT02227251 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT02227251?

The interventions under investigation include: Selinexor (DRUG).

Who is sponsoring clinical trial NCT02227251?

This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02227251 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02227251's enrollment target sits among peer trials

244 24th of 114 higher than 91 of 114 other Diffuse Large B Cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04317534 · 244 participants · Phase 2

    Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

  • NCT04683250 · 244 participants · Phase 1

    Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

  • NCT04686305 · 244 participants · Phase 1

    Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

  • NCT05703269 · 244 participants · NA

    Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT02227251

Source: ClinicalTrials.gov NCT02227251, the US trial registry maintained by the National Library of Medicine. NCT02227251 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.